STMN logo

Straumann Holding AG Stock Price

SWX:STMN Community·CHF 15.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 33 Fair Values set on narratives written by author

STMN Share Price Performance

CHF 97.28
-10.57 (-9.80%)
CHF 108.78
Fair Value
CHF 97.28
-10.57 (-9.80%)
10.6% undervalued intrinsic discount
CHF 108.78
Fair Value
Price CHF 97.28
AnalystConsensusTarget CHF 108.78
AnalystLowTarget CHF 83.00
AnalystHighTarget CHF 130.00

STMN Community Narratives

·
Fair Value CHF 108.78 10.6% undervalued intrinsic discount

STMN: Future Performance Will Depend On U S Operational Recovery And Margin Stability

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
·
Fair Value CHF 83 17.2% overvalued intrinsic discount

Rising Regulation And Cost Pressures Will Curb Premium Dental Demand

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value CHF 130 25.2% undervalued intrinsic discount

Emerging Markets And Aging Populations Will Redefine Dental Care

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CHF 108.78
10.6% undervalued intrinsic discount
Revenue
8.13% p.a.
Profit Margin
19.72%
Future PE
30.22x
Price in 2029
CHF 122.98

Trending Discussion

No trending discussion available.

Updated Narratives

STMN logo

STMN: China Rebound And Margin Recovery Will Support Future Multiple Re-Rating

Fair Value: CHF 130 25.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
STMN logo

STMN: Rich Multiples Will Likely Limit Upside Despite Higher Street Optimism

Fair Value: CHF 83 17.2% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
STMN logo

STMN: Raised Profitability Guidance And Refined Assumptions Support Balanced Forward Outlook

Fair Value: CHF 108.78 10.6% undervalued intrinsic discount
15 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards

Straumann Holding AG Key Details

CHF 2.6b

Revenue

CHF 779.1m

Cost of Revenue

CHF 1.8b

Gross Profit

CHF 1.5b

Other Expenses

CHF 356.7m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 19, 2026
2.24
70.10%
13.69%
11.5%
View Full Analysis

About STMN

Founded
1954
Employees
11570
CEO
Guillaume Daniellot
WebsiteView website
www.straumann.com

Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally. It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments. The company offers dental implants, instruments, CADCAM prosthetics, orthodontic and clear aligners, biomaterials, and digital equipment and solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. It also provides implant systems, components, and related instruments, as well as healing components, materials and surfaces, surgical sets and instruments, and guided surgery and navigation products; prosthetics, including angled solutions, connections, components, and molar solutions; intra-oral and lab scanners, milling machines, dynamic navigation systems, and 3D printers; consumables, such as blocks, discs, resins, titanium bases, and abutment blanks, as well as scan bodies, analogs, and sleeves; online education; and dentists and dental labs solutions. In addition, the company offers regenerative solutions for tooth preservation, implant-site management, and implant preservation; scanner hardware, software licenses, sterile-packaged products, customer training, and other products; and logistics and supply chain services. Further, it provides thermoplastics; implant treatment referral; high-tech materials; artificial intelligence solutions for dental applications; and 3D orthodontic treatment animations. The company sells its products under the Straumann, Neodent, Medentika, Anthogyr, ClearCorrect, NUVO, and other brands through a network of distribution subsidiaries and partners, and third-party distributors, as well as through its e-shop. It serves clinicals needs, patient segments, and healthcare systems. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Recent STMN News & Updates

Narrative Update Jul 20

STMN: China Rebound And Margin Recovery Will Support Future Multiple Re-Rating

Straumann Holding's analyst fair value estimate has been revised from CHF 123.00 to CHF 130.00. This reflects recent upward moves in Street price targets as analysts point to updated views on discount rates, profit margins and future P/E assumptions.
Narrative Update Jul 06

STMN: Rich Multiples Will Likely Limit Upside Despite Higher Street Optimism

Straumann Holding's fair value estimate has been nudged higher to CHF 83.00, reflecting a series of upward price target revisions from analysts who cite updated assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on Straumann Holding has pointed to a split in sentiment, with some firms lifting price targets while others flag risks around valuation and the company’s ability to deliver on growth expectations.
Narrative Update Jun 22

STMN: Raised Profitability Guidance And Refined Assumptions Support Balanced Forward Outlook

Straumann Holding's analyst price target has been adjusted by CHF 1, supported by analysts' updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E multiples, along with recent Street research that includes price target increases to CHF 120 at Barclays and smaller upward revisions at Morgan Stanley and Citi. Analyst Commentary Recent research around Straumann Holding shows a cluster of upward price target revisions, which signals that covering analysts are revisiting their assumptions on valuation, growth and execution risk.

Recent updates

No updates